MVP与EP方案治疗晚期非小细胞肺癌疗效对比观察

A Comparison of MVP Regimen Verus EP Regimen in the Treatment for Advanced Non - small Cell Lung Cancer

目的 观察比较MVP方案EP方案两种不同化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效和毒性。方法 晚期NSCLC89例,用MVP方案31例,用EP方案58例,进行有效率和毒性的统计。结果 MVP组有效率35.5％(11/31),EP组有效率31.0％(18/58),两组无显著性差异(P>0.05)。两组剂量限制毒性均为骨髓抑制,白细胞下降占66.2％,Ⅲ～Ⅳ度下降MVP组为6.5％,EP组为6.7％。其次为胃肠道毒性和脱发,均为Ⅰ～Ⅱ度。结论 MVP方案治疗晚期NSCLC的疗效和毒性与EP方案相仿,均为治疗晚期非小细胞肺癌安全有效的化疗方案。

Objective To compare the efficacy and toxicity in MVP and EP regimens for advanced non-small cell lung cancer. Methods The clinical data of 89 cases with advanced NSCLC treated with MVP regimen(31 cases) and EP regimen (58 cases) were analyzed. Results The response rate was 35.5% in patients treated with MVP, 31.0% in those treated with EP. The most common toxic reaction in two groups was myelosuppression. Conclusion MVP and EP are effective and safe chemotherapeutic projects for the treatment of advanced NSCLC patients.